| Date Filed | Type | Description |
| 10/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 10/04/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 10/03/2023 |
4
| Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/|
Txns:
| Bought 24,670 shares
@ $13.63, valued at
$336.3k
|
|
| 09/28/2023 |
4
| Fairmount Funds Management LLC (10% Owner) has filed a Form 4 on Dianthus Therapeutics, Inc. /DE/|
Txns:
| Bought 30,000 shares
@ $13.15, valued at
$394.5k
|
|
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/01/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/31/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 07/17/2023 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 05/19/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/15/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 6.7% stake in Magenta Therapeutics, Inc. |
| 05/15/2023 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 05/03/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 05/03/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/03/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement Interactive Data |
| 03/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
| 03/31/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in MAGENTA THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| Aquilo Capital Management, LLC reports a 0% stake in Magenta Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| GILDER GAGNON HOWE & CO LLC reports a 0.7% stake in Magenta Therapeutics, Inc. |
| 02/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
4
| Third Rock Ventures IV, L.P. (10% Owner) has filed a Form 4 on Magenta Therapeutics, Inc.|
Txns:
| Sold 2,200,000 shares
@ $0.83, valued at
$1.8M
Sold 1,500,000 shares
@ $0.82, valued at
$1.2M
|
|
| 02/07/2023 |
8-K
| Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce... |
| 02/02/2023 |
8-K
| Quarterly results |
| 01/25/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/13/2022 |
8-K
| Quarterly results |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|